ENOVIS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.39 USD | -1.49% |
|
-4.02% | -10.05% |
| May. 16 | Transcript : Enovis Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 04:20 PM | |
| May. 02 | Enovis Q1 Shares Fall Following Q1 Results | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.05% | 2.76B | B- | ||
| +10.37% | 126B | A- | ||
| -5.61% | 11.3B | A- | ||
| +4.83% | 9.16B | C | ||
| +36.53% | 5.46B | B+ | ||
| -25.10% | 4.53B | C | ||
| +8.61% | 3.45B | C- | ||
| -10.99% | 2.09B | - | - | |
| -10.20% | 2B | - | ||
| -23.65% | 1.77B | - | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ENOV Stock
- Ratings Enovis Corporation